All In Biotech

NDA 050786 · Labs Juvise

Pylera

Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride · Oral · Nitroimidazole Antimicrobial

Novel

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Sep 28, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

59

9 Phase 3, 6 recruiting

FAERS reports

1,133

940 serious, 18 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POTENTIAL FOR CARCINOGENICITY Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans [see Warning and Precautions (5.1) ]. WARNING: POTENTIAL FOR CARCINOGENICITY See full prescribing information for complete boxed warning. Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans ( 5.1 ).

What it is approved for

From the label in effect Jun 29, 2026.

PYLERA is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease PYLERA in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: PYLERA is a combination of antibacterial agents (metronidazole and tetracycline hydrochloride) and bismuth subcitrate potassium [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 28, 2006 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelReviewLetter
1 products under this application
  • PYLERA · BISMUTH SUBCITRATE POTASSIUM 140MG; METRONIDAZOLE 125MG; TETRACYCLINE HYDROCHLORIDE 125MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Bismuth Subcitrate" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea123
  • headache111
  • diarrhoea102
  • dizziness81
  • faeces discoloured81
  • asthenia76
  • vomiting75
  • off label use68
  • pruritus61
  • fatigue60
  • abdominal pain upper55
  • dyspnoea54

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200811
200918
20107
20112
20123
201335
201446
201573
201680
201783
2018106
201986
2020113
202194
202281
202353
202481
202595
202666

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pylera (Bismuth/Metronid/Tetracycline)

2024 spending

$168K

Beneficiaries

514

538 claims

Per beneficiary

$327

$2.48 per unit

View as table
YearSpending
2020$3,992,297
2021$3,871,579
2022$4,439,708
2023$1,990,221
2024$168,132

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 276 on PubMed

Sponsor: Labs Juvise

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.